Trial reportJournal of neurovirology2016
Peripheral neuropathy in HIV patients in sub-Saharan Africa failing first-line therapy and the response to second-line ART in the EARNEST trial.
Trial report in Journal of neurovirology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Higher iron stores and the HFE 187C>G variant delay onset of peripheral neuropathy during combination antiretroviral therapy.PloS one · 2020Trial
- Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.The Lancet. Infectious diseases · 2018Trial
- Exploratory multidimensional cardiovascular health-related profiles among people living with HIV who attend two urban antiretroviral clinics in Panama.Discover public health · 2026Article
- Peripheral Neuropathy in Virologically Suppressed People Living with HIV: Evidence from the PIVOT Trial.Viruses · 2023Article
- A BAYESIAN DECISION FRAMEWORK FOR OPTIMIZING SEQUENTIAL COMBINATION ANTIRETROVIRAL THERAPY IN PEOPLE WITH HIV.The annals of applied statistics · 2023Article
- An Analysis of Peripheral Neuropathy Symptom Characteristics in HIV.Journal of medicine and healthcare · 2022Article
- Evaluation of a screening tool for the identification of neurological disorders in rural Uganda.Journal of the neurological sciences · 2021Article
- HIV-related Neuropathy: Pathophysiology, Treatment and Challenges.Journal of neurology and experimental neuroscience · 2021Article
- Peripheral neuropathy in patients with human immunodeficiency viral infection at a tertiary hospital in Ghana.Journal of neurovirology · 2019Article
- Neurological disorders in HIV in Africa: a review.African health sciences · 2019Review
- The physical sequelae of perinatally acquired HIV in adolescents: a research proposal.BMC research notes · 2019Article
- Article
- HIV-associated sensory polyneuropathy and neuronal injury are associated with miRNA-455-3p induction.JCI insight · 2018Article
- Adverse Drug Reactions Among Patients Initiating Second-Line Antiretroviral Therapy in South Africa.Drug safety · 2018Article
- Factors associated with distal symmetric polyneuropathies in adult Zambians: A cross-sectional, observational study of the role of HIV, non-antiretroviral medication exposures, and nutrition.Journal of the neurological sciences · 2018Observational
- Psychological Factors Associated With Painful Versus Non-Painful HIV-Associated Sensory Neuropathy.AIDS and behavior · 2018Article
- Article
- Nucleoside reverse transcriptase inhibitors (NRTIs) induce proinflammatory cytokines in the CNS via Wnt5a signaling.Scientific reports · 2017Article
- The relationship between lower limb muscle strength and lower extremity function in HIV disease.The South African journal of physiotherapy · 2017Article
- Prevalence and incidence of neurological disorders among adult Ugandans in rural and urban Mukono district; a cross-sectional study.BMC neurology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sensory peripheral neuropathy (PN) remains a common complication in HIV-positive patients despite effective combination anti-retroviral therapy (ART). Data on PN on second-line ART is scarce. We assessed PN using a standard tool in patients failing first-line ART and for 96 weeks following a switch to PI-based second-line ART in a large Randomised Clinical Trial in Sub-Saharan Africa. Factors associated with PN were investigated using logistic regression. Symptomatic PN (SPN) prevalence was 22% at entry (N = 1,251) and was associated (p < 0.05) with older age (OR = 1.04 per year), female gender (OR = 1.64), Tuberculosis (TB; OR = 1.86), smoking (OR = 1.60), higher plasma creatinine (OR = 1.09 per 0.1 mg/dl increase), CD4 count (OR = 0.83 per doubling) and not consuming alcohol (OR = 0.55). SPN prevalence decreased to 17% by week 96 (p = 0.0002) following similar trends in all study groups (p = 0.30). Asymptomatic PN (APN) increased over the same period from 21 to 29% (p = 0.0002). Signs suggestive of PN (regardless of symptoms) returned to baseline levels by week 96. At weeks 48 and 96, after adjusting for time-updated associations above and baseline CD4 count and viral load, SPN was strongly associated with TB (p < 0.0001). In summary, SPN prevalence was significantly reduced with PI-based second-line therapy across all treatment groups, but we did not find any advantage to the NRTI-free regimens. The increase of APN and stability of PN-signs regardless of symptoms suggest an underlying trend of neuropathy progression that may be masked by reduction of symptoms accompanying general health improvement induced by second-line ART. SPN was strongly associated with isoniazid given for TB treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.